Short Interest in Biopharmx Corp (BPMX) Rises By 2.3%

Biopharmx Corp (NYSEAMERICAN:BPMX) saw a large increase in short interest during the month of December. As of December 29th, there was short interest totalling 6,319,421 shares, an increase of 2.3% from the December 15th total of 6,178,513 shares. Based on an average daily volume of 2,712,891 shares, the days-to-cover ratio is currently 2.3 days. Approximately 6.0% of the company’s stock are sold short.

Biopharmx (NYSEAMERICAN:BPMX) traded up $0.01 during trading hours on Wednesday, hitting $0.13. 5,858,800 shares of the stock were exchanged, compared to its average volume of 5,777,920. The company has a market cap of $14.93, a P/E ratio of -0.48 and a beta of 1.33. Biopharmx has a one year low of $0.10 and a one year high of $0.90.

Biopharmx (NYSEAMERICAN:BPMX) last announced its quarterly earnings results on Thursday, December 7th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05).

In related news, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the firm’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $0.20, for a total value of $59,278.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Stephen Morlock bought 330,000 shares of the stock in a transaction that occurred on Friday, November 24th. The stock was purchased at an average price of $0.15 per share, for a total transaction of $49,500.00. The disclosure for this purchase can be found here.

A number of equities analysts have recently commented on BPMX shares. Maxim Group reaffirmed a “buy” rating and set a $1.50 price objective on shares of Biopharmx in a report on Friday, December 8th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Biopharmx in a report on Tuesday, September 19th.

ILLEGAL ACTIVITY NOTICE: This report was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply